Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays.

Urologic oncology - 1 Sept 2020

Pritchard John J G, Hamilton Graham, Hurst Carolyn D, Fraser Sioban, Orange Clare, Knowles Margaret A, Jones Robert J, Leung Hing Y, Iwata Tomoko

Abstract excerpt

OBJECTIVES: Real-time monitoring of disease status would be beneficial for timely decision making in the treatment of urothelial cancer (UC), and may accelerate the evaluation of clinical trials. Use of cell free tumor DNA (cftDNA) as a biomarker in liquid biopsy is minimally invasive and its successful use has been reported in various cancer types, including UC. The objective of this study was to evaluate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Transitional Cell

Share to Circulating Tumor DNA

Share to Feasibility Studies

Share to Liquid Biopsy

Share to Polymerase Chain Reaction

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 32532529
DOI: 10.1016/j.urolonc.2020.05.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays.PMID 32532529Read ↗

Development of Sensitive Droplet Digital PCR Assays for Detecting Urinary TERT Promoter Mutations as Non-Invasive Biomarkers for Detection of Urothelial CancerSemantic proximity Read ↗

Simplex Droplet Digital PCR Assays for the Detection of TERT Promoter Mutations in Urine Samples for the Non-invasive Diagnosis of Urothelial Cancer.Semantic proximity Read ↗

Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective.Semantic proximity Read ↗

Liquid biopsies for bladder cancerSemantic proximity Read ↗

Diagnostic potential of TERT promoter and FGFR 3 mutations in urinary cell‐free DNA in upper tract urothelial carcinomaSemantic proximity Read ↗

Current and Emerging Applications of Droplet Digital PCR in Oncology: An Updated Review.Semantic proximity Read ↗

Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.Semantic proximity Read ↗

Optimized targeted sequencing of cell-free plasma DNA from bladder cancer patients.Semantic proximity Read ↗

Diagnostic performance of Uromonitor and TERTpm ddPCR urine tests for the non-invasive detection of bladder cancer.Semantic proximity Read ↗

TERTmonitor Efficacy and Performance in Detecting Mutations by Droplet Digital PCR.Semantic proximity Read ↗

Digital PCR-Based Uromonitor for Molecular Detection of Bladder Cancer: A Multicenter Validation Study Comparing Quantitative PCR and Urine Cytology.Semantic proximity Read ↗

Detection of circulating tumor DNA (ctDNA) by digital droplet polymerase chain reaction (dd-PCR) in liquid biopsies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.